Yuhan Corporation - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 60 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Yuhan Corporation - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Yuhan Corporation - Product Pipeline Review - 2014', provides an overview of the Yuhan Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Yuhan Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Yuhan Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Yuhan Corporation's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Yuhan Corporation's pipeline products

Reasons to buy

- Evaluate Yuhan Corporation's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Yuhan Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Yuhan Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Yuhan Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Yuhan Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Yuhan Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Yuhan Corporation Snapshot 7
Yuhan Corporation Overview 7
Key Information 7
Key Facts 7
Yuhan Corporation - Research and Development Overview 8
Key Therapeutic Areas 8
Yuhan Corporation - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Yuhan Corporation - Pipeline Products Glance 16
Yuhan Corporation - Late Stage Pipeline Products 16
Phase III Products/Combination Treatment Modalities 16
Yuhan Corporation - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Yuhan Corporation - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Yuhan Corporation - Drug Profiles 21
(atorvastatin calcium + losartan potassium) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
(rosuvastatin + telmisartan) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(rosuvastatin + valsartan) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
bilastine 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
YHD-001 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
YH-14618 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
YH-4808 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
YHD-1023 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
YHD-14642 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
(rosuvastatin + metformin) 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
YH-12852 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
YHB-14112 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
YH-1176 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
YH-1177 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
YH-14619 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
YH-14810 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
YH_Bio1 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
YH_Bio2 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
YH_Chem1 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
YH_Chem2 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
YH_Chem3 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
YH_Chem4 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
YH_Chem5 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Drug to Agonize PPAR for Type 2 Diabetes 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
YH-GKA 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Yuhan Corporation - Pipeline Analysis 46
Yuhan Corporation - Pipeline Products by Target 46
Yuhan Corporation - Pipeline Products by Route of Administration 48
Yuhan Corporation - Pipeline Products by Molecule Type 49
Yuhan Corporation - Pipeline Products by Mechanism of Action 50
Yuhan Corporation - Recent Pipeline Updates 52
Yuhan Corporation - Dormant Projects 54
Yuhan Corporation - Company Statement 55
Yuhan Corporation - Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Yuhan Corporation - Key Manufacturing Facilities 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Tables
Yuhan Corporation, Key Information 7
Yuhan Corporation, Key Facts 7
Yuhan Corporation - Pipeline by Indication, 2014 9
Yuhan Corporation - Pipeline by Stage of Development, 2014 11
Yuhan Corporation - Monotherapy Products in Pipeline, 2014 12
Yuhan Corporation - Combination Treatment Modalities in Pipeline, 2014 13
Yuhan Corporation - Partnered Products in Pipeline, 2014 14
Yuhan Corporation - Partnered Products/ Combination Treatment Modalities, 2014 15
Yuhan Corporation - Phase III, 2014 16
Yuhan Corporation - Phase II, 2014 17
Yuhan Corporation - Phase I, 2014 18
Yuhan Corporation - Preclinical, 2014 19
Yuhan Corporation - Discovery, 2014 20
Yuhan Corporation - Pipeline by Target, 2014 47
Yuhan Corporation - Pipeline by Route of Administration, 2014 48
Yuhan Corporation - Pipeline by Molecule Type, 2014 49
Yuhan Corporation - Pipeline Products by Mechanism of Action, 2014 51
Yuhan Corporation - Recent Pipeline Updates, 2014 52
Yuhan Corporation - Dormant Developmental Projects,2014 54
Yuhan Corporation, Other Locations 56
Yuhan Corporation, Subsidiaries 57
Yuhan Corporation, Key Manufacturing Facilities 58